Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
A phase 3 trial testing LM-302 in gastric & gastro-oesophageal junction cancer, now recruiting.
Overview
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 3 interventional study registered as NCT07385703, led by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Planned enrolment is 752 participants (estimated). The study started in 2026-04-15 and primary completion is expected in 2028-10. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialTo Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialClinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag ctgov-ingest.